iScience (Feb 2023)

Hyperphosphorylation of hepatic proteome characterizes nonalcoholic fatty liver disease in S-adenosylmethionine deficiency

  • Aaron E. Robinson,
  • Aleksandra Binek,
  • Komal Ramani,
  • Niveda Sundararaman,
  • Lucía Barbier-Torres,
  • Ben Murray,
  • Vidya Venkatraman,
  • Simion Kreimer,
  • Angela Mc Ardle,
  • Mazen Noureddin,
  • David Fernández-Ramos,
  • Fernando Lopitz-Otsoa,
  • Virginia Gutiérrez de Juan,
  • Oscar Millet,
  • José M. Mato,
  • Shelly C. Lu,
  • Jennifer E. Van Eyk

Journal volume & issue
Vol. 26, no. 2
p. 105987

Abstract

Read online

Summary: Methionine adenosyltransferase 1a (MAT1A) is responsible for hepatic S-adenosyl-L-methionine (SAMe) biosynthesis. Mat1a−/− mice have hepatic SAMe depletion, develop nonalcoholic steatohepatitis (NASH) which is reversed with SAMe administration. We examined temporal alterations in the proteome/phosphoproteome in pre-disease and NASH Mat1a−/− mice, effects of SAMe administration, and compared to human nonalcoholic fatty liver disease (NAFLD). Mitochondrial and peroxisomal lipid metabolism proteins were altered in pre-disease mice and persisted in NASH Mat1a−/− mice, which exhibited more progressive alterations in cytoplasmic ribosomes, ER, and nuclear proteins. A common mechanism found in both pre-disease and NASH livers was a hyperphosphorylation signature consistent with casein kinase 2α (CK2α) and AKT1 activation, which was normalized by SAMe administration. This was mimicked in human NAFLD with a metabolomic signature (M-subtype) resembling Mat1a−/− mice. In conclusion, we have identified a common proteome/phosphoproteome signature between Mat1a−/− mice and human NAFLD M-subtype that may have pathophysiological and therapeutic implications.

Keywords